에이스파마

비상장계속사업자

Acepharma

박재규

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios — 100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

에이스파마

Business Reg. No. 2048189829 · CEO 박재규

I.Investment Overview

Target에이스파마 (2048189829)
Investment—
Post-deal stake—
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명에이스파마
영문명Acepharma
대표자박재규
사업자등록번호2048189829
법인등록번호1101113161603
설립일2005.02.14

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW135.82021140.120221512023117.82024110.82025
영업이익100M KRW11.2202122.4202216.820232.2202414.32025
순이익100M KRW7.6202115.520221020238.520249.72025
Item20252024202320222021
자산총계216.1억원207.9억원236.8억원247.2억원239.8억원
부채총계92억원93.4억원123.7억원139.1억원141.3억원
자본총계124.2억원114.5억원113.1억원108억원98.5억원
매출액110.8억원117.8억원151억원140.1억원135.8억원
영업이익14.3억원2.2억원16.8억원22.4억원11.2억원
순이익9.7억원8.5억원10억원15.5억원7.6억원

VI.Financial Ratios

FY2025 basis

12.87%

영업이익률

8.72%

순이익률

4.47%

ROA

7.78%

ROE

74.06%

부채비율

57.45%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation—
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

에이스파마 투심보고서 | Alpha Lenz